Deals and Financings
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.Meanwhile, Sanofi, a Paris biopharma, acquired a right-of-first-refusal for global rights to a ROCK2 inhibitor developed by Graviton Bioscience, which in-licensed the candidate from Beijing Tide Pharma.
Government and Regulatory
Recently, US legislators proposed a new law designed to protect genomic information of US citizens from Chinese biopharma companies, mentioning BGI and WuXi Bio as companies affiliated with China’s Army.
Trials and Approvals
Jinan Qilu Pharma announced that results from a Phase III trial of its next-gen oral ALK TKI for NSCLC were published in an international journal. Meanwhile, Biosyngen, a Singapore-Guangzhou cell therapy company, was granted US Fast Track designation for a clinical stage tumor-infiltrating lymphocyte (TIL) for liver cancer indications.Guangzhou Bio-Thera Solutions has begun dosing patients in a China Phase IA/IIB clinical trial to test the efficacy and safety of an anti-OX40 inhibitor in patients with atopic dermatitis. Additionally, Suzhou Duality Biologics and Germany’s BioNTech received US Fast Track designation for their partnered ADC drug candidate to treat platinum-resistant ovarian cancer.Biosion USA, an arm of Nanjing Biosion, has been cleared to begin US trials of BSI-082, a novel anti-SIRPα mAb targeting solid tumor cancers. Gracell Biotech, a Suzhou-San Diego CAR-T company, was approved to begin a US Phase 1 clinical trial of its FasTCAR candidate in the US as an early-line multiple myeloma treatment.Finally, Suzhou Vesicure reported that its extracellular vesicles successfully carried siRNA cargo targeting a KRAS mutation in a CDX mouse tumor model.More By This Author:Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From ChinaWeek in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure TherapyWeek In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
